AstraZeneca has agreed a deal worth up to $247 million with US generative artificial intelligence (GenAI) company Absci that will focus on the discovery of a new antibody-based drug for cancer.

With the advent of […] Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that harnesses deep learning AI and synthetic biology to ...

Owkin has expertise in AI-enabled target discovery and agentic AI, which potentially meshes well with Absci’s AI-enabled drug design capabilities. The companies plan on co-developing therapeutic ...

The stake comes alongside an agreement for Vancouver, Washington-based Absci to use AMD chips and software to power its drug discovery workloads, including a biologic drug design platform using ...

Absci Corporation’s ABSI share price has dipped by 5.12%, which has investors questioning if this is right time to buy.

Absci Corp is the Artificial intelligence ... It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

A research team from the University of Oklahoma has pioneered a method that could accelerate drug discovery and reduce ...

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech ...

Absci Corporation’s ABSI share price has surged by 5.86%, which has investors questioning if this is right time to sell.

Recursion, a biotechnology company focused on using artificial intelligence to accelerate drug discovery ... Inc., Simulations Plus Inc. and Absci Corp., also saw double-digit gains in extended ...

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech ...